Piperacillin/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis
Infection · 2025
DOI: 10.1007/s15010-024-02447-y ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Infection, 2025. Verfasst von Lorenzo Onorato und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Via L. Armanni 5, Naples, 8…. Hauptthemen laut MEDLINE: beta-Lactamases, Cefepime, Piperacillin, Tazobactam Drug Combination, Carbapenems. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The best treatment for bloodstream infections (BSI) due to chromosomal AmpC (c-AmpC) producing Enterobacterales is not clearly defined. OBJECTIVES: To describe the clinical and microbiological outcomes of patients treated with piperacillin/tazobactam, cefepime or carbapenems for bloodstream infections (BSIs) due to c-AmpC beta-lactamase-producing strains. DATA SOURCES: We searched MEDLINE, the Cochrane Library and EMBASE to screen original reports published up to January 2024. STUDY ELIGIBILITY CRITERIA: RCTs and observational studies investigating all-cause mortality, clinical failure, microbiological failure or rate of ADRs of patients treated with piperacillin/tazobactam, cefepime or carbapenems. PARTICIPANTS: Patients with bloodstream infections due to c-AmpC producing bacteria. INTERVENTIONS: Piperacillin/tazobactam, cefepime or carbapenems as targeted treatment. ASSESSMENT OF RISK OF BIAS: We used the Cochrane Risk of Bias Tool for RCTs, and the Newcastle Ottawa scale for observational studies. METHODS OF DATA SYNTHESIS: We conducted a meta-analysis pooling Risk ratios (RRs) through random effect models. RESULTS: We screened 1,720 original reports, and 20 studies (1 RCTs, 1 case-control study, 18 cohort studies) were included in the analysis, for a total of 2,834 patients. When comparing piperacillin/tazobactam with alternative treatments (cefepime or carbapenems), no significant difference in mortality rate was observed between the treatment groups (RR: 1.1; 95% CI: 0.76-1.58, p = 0.61), while an higher rate of microbiological failure (RR: 1.80; 95% CI: 1.15-2.82, p = 0.01) and clinical failure (RR: 1.54; 95% CI: 1.00-2.40, p = 0.05) was observed among patients receiving piperacillin/tazobactam. No difference was observed in microbiological and clinical failure rate among patients treated with cefepime or carbapenems, with a lower mortality rate in those receiving cefepime (RR: 0.74; 95% CI: 0.59-0.94, p = 0.014). CONCLUSIONS: Cefepime represents an excellent alternative to carbapenems for BSI due to AmpC-producing strains, whereas piperacillin/tazobactam is associated with a higher rate of clinical and microbiological failure. There is an urgent need for randomized clinical trials that aim to define the best carbapenem-sparing strategy in these infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Via L. Armanni 5, Naples, 80131, Italy.
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Via L. Armanni 5, Naples, 80131, Italy. nicola.coppola@unicampania.it.
Zitieren
APA
Onorato, L., de Luca, I., Salvati, A., Monari, C., & Coppola, N. (2025). Piperacillin/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis. Infection. https://doi.org/10.1007/s15010-024-02447-y
Vancouver
Onorato L, de Luca I, Salvati A, Monari C, Coppola N. Piperacillin/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis. Infection. 2025. doi:10.1007/s15010-024-02447-y
BibTeX
@article{Onorato2025,
author = {Onorato, Lorenzo and de Luca, Ilaria and Salvati, Annabella and Monari, Caterina and Coppola, Nicola},
title = {Piperacillin/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis},
journal = {Infection},
year = {2025},
doi = {10.1007/s15010-024-02447-y}
}
EUVIMED